SEGMENT INFORMATION (Tables)

9 Months Ended

Sep. 30, 2025

Segment Reporting [Abstract]

SCHEDULE OF SEGMENT REVENUE

	Three months ended September 30,						Nine months ended September 30,
	2025			2024			2025			2024
Revenues		2,523			1,810			5,830			5,060
Cost of Revenues:
Material and Labor		1,391			1,209			3,554			3,373
Other cost of revenues		268			187			807			650
Total Cost of Revenues		1,659			1,396			4,361			4,023
Research and development (R&D)
Payroll and Benefits		1,089			715			3,063			2,066
Share based compensation		576			644			1,889			1,795
Clinical trials		1,105			1,289			3,401			3,240
Other R&D		865			1,267			3,175			2,840
Total Research and development		3,635			3,915			11,528			9,941
Selling and marketing (S&M)
Payroll and Benefits		2,975			907			7,732			2,522
Share based compensation		567			277			1,379			791
Other S&M		850			288			2,203			841
Total Selling and marketing		4,392			1,472			11,314			4,154
General and administrative (G&A)
Payroll and Benefits		1,707			889			5,015			2,539
Share based compensation		2,351			1,460			6,051			4,970
Other G&A		1,830			1,140			5,091			3,569
Total General and administrative		5,888			3,489			16,157			11,078
Financial Income, net;		343			572			505			1,305
Segment net Loss		(12,708	)		(7,890	)		(37,025	)		(22,831	)